Nicotinamide adenine dinucleotide biology in aging and supplementation

Fundamental Biochemistry and Biological Function

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide that serves as a ubiquitous and indispensable coenzyme in all living cells ¹². At the most fundamental level, NAD+ operates as a primary redox cofactor in cellular metabolism, oscillating continuously between its oxidized form (NAD+) and its reduced form (NADH). This dynamic exchange facilitates the transfer of electrons required for glycolysis, the tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation, ultimately driving the production of adenosine triphosphate (ATP) ³¹.

Beyond its foundational role in energy metabolism and cellular respiration, NAD+ functions as an obligatory co-substrate for several critical classes of signaling enzymes. These include the sirtuin family of protein deacylases (SIRT1-7 in mammals), poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthetases, which encompass the transmembrane glycoproteins CD38 and CD157 ¹². Unlike redox reactions where the NAD+ molecule is preserved and continuously recycled, these signaling enzymes actively cleave the high-energy β-glycosidic bond between the nicotinamide and ribose moieties to extract ADP-ribose ³. Consequently, these enzymatic reactions actively consume the cellular NAD+ pool. Because metabolic regulation, DNA repair, and epigenetic signaling constantly drain cellular NAD+ reserves, continuous biosynthesis and recycling are required to maintain physiological homeostasis ⁶⁷⁸.

A profound and systemic decline in NAD+ bioavailability is a well-documented hallmark of biological aging ³¹⁰. In some human and mammalian tissues, NAD+ concentrations fall by as much as 50% between youth and middle age ⁴¹²⁵. This depletion directly impairs the enzymatic activity of sirtuins and PARPs, which contributes to mitochondrial dysfunction, compromised DNA repair, chronic inflammation, and the broader pathophysiology of age-related metabolic and neurodegenerative diseases ³⁶.

Metabolic Biosynthesis Pathways

Mammalian cells cannot rely solely on existing NAD+ pools; they must continuously synthesize the molecule through three distinct metabolic pathways. These pathways utilize varying dietary precursors - primarily the amino acid tryptophan and the forms of vitamin B3 - to construct the NAD+ molecule ⁸⁷⁸.

De Novo Biosynthesis

The de novo pathway synthesizes NAD+ from scratch, beginning with the essential dietary amino acid L-tryptophan. Tryptophan undergoes a complex, multi-step enzymatic cascade known as the kynurenine pathway to form quinolinic acid, which is then converted into nicotinic acid mononucleotide (NaMN) ⁸³. Because it is energetically expensive and requires multiple rate-limiting steps, the de novo pathway is highly inefficient. It operates primarily in the liver and the kidneys, functioning as a secondary, systemic backup rather than the primary mechanism for meeting cellular NAD+ demands ⁸⁷⁸.

The Preiss-Handler Pathway

The Preiss-Handler pathway synthesizes NAD+ using dietary nicotinic acid (NA), the specific form of vitamin B3 commonly referred to as niacin. Nicotinic acid enters the cell via specific transporters (such as SLC5A8 or SLC22A13) and is converted into nicotinic acid mononucleotide (NaMN) ⁸. NaMN is subsequently adenylated to form nicotinic acid adenine dinucleotide (NaAD). In the final step, NaAD is amidated by the enzyme NAD synthetase to produce NAD+ ⁶⁹. While highly effective at raising NAD+ levels, the therapeutic administration of high-dose nicotinic acid is often limited by severe cutaneous flushing and gastrointestinal distress, triggered by the activation of GPR109A receptors ¹⁰¹⁹.

The Salvage Pathway and Late-Stage Precursors

The salvage pathway is the dominant route for NAD+ maintenance in mammalian cells, responsible for recycling up to 85% of total cellular NAD+ ⁸. This pathway functions as an energy-efficient recycling loop. When signaling enzymes like sirtuins or PARPs consume NAD+, they release nicotinamide (NAM) as a byproduct. To prevent NAM from accumulating and inhibiting cellular functions, the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the conversion of NAM into nicotinamide mononucleotide (NMN) ⁷¹¹. NMN is then rapidly converted back into NAD+ by a group of ATP-dependent isoenzymes known as nicotinamide mononucleotide adenylyltransferases (NMNAT1-3), which reside in varying subcellular compartments ⁷.

To bypass the NAMPT bottleneck - which is prone to downregulation during biological aging - research and therapeutic formulations rely on direct administration of late-stage precursors. NMN acts as a direct, one-step precursor to NAD+ ⁷. Another prevalent precursor, nicotinamide riboside (NR), enters the salvage pathway by bypassing NAMPT entirely. Upon entering the cell, NR is phosphorylated by nicotinamide riboside kinases (NRK1/2) directly into NMN, seamlessly feeding into the final step of the salvage cycle ⁸⁷.

Dietary Precursors of Nicotinamide Adenine Dinucleotide

Mechanisms of Age-Related Depletion

Historically, the decline in NAD+ levels associated with aging was hypothesized to stem from a reduction in biosynthetic capacity. However, advanced metabolic tracing studies utilizing isotope-labeled precursors indicate that baseline NAD+ synthesis pathways remain largely functional in older organisms. Instead, the systemic deficit is primarily driven by substantially heightened catabolic consumption ³¹⁰.

CD38 Hyperactivation and Inflammaging

A primary driver of this catabolic drain is the transmembrane NADase enzyme CD38. Advanced aging is characterized by a state of chronic, low-grade, sterile inflammation commonly termed "inflammaging." As biological age advances, pro-inflammatory M1-like macrophages and senescent cells accumulate heavily in visceral adipose tissue and other organs ¹⁰⁶. These immune cells secrete an array of inflammatory cytokines that profoundly upregulate the expression and activity of CD38.

This creates a self-sustaining cycle where chronic inflammation drives CD38 hyperactivation, which in turn cleaves vast quantities of NAD+ to produce secondary signaling metabolites like cyclic ADP-ribose ³¹⁰. The severity of this drain is evident in preclinical models: CD38 knockout mice exhibit tissue NAD+ levels ten to twenty times higher than wild-type counterparts and maintain youth-like metabolic parameters well into chronological age ³³. Furthermore, pharmacological suppression of CD38 utilizing inhibitors like the synthetic molecule 78c or the flavonoid apigenin has been shown to successfully restore NAD+ levels, improve mitochondrial function, and extend median lifespan by approximately 10% in naturally aged mice ¹⁰⁶.

Poly(ADP-ribose) Polymerases and Genomic Stress

The second major consumptive sink for NAD+ is the poly(ADP-ribose) polymerase (PARP) family of enzymes, principally PARP1. PARP1 acts as a critical sensor for DNA damage. When activated by single-strand or double-strand DNA breaks, PARP1 aggressively consumes NAD+ to synthesize poly(ADP-ribose) chains, which recruit necessary repair proteins to the site of genomic injury ³⁶.

Aging cells naturally accumulate DNA damage due to oxidative stress, environmental factors, and telomere attrition. Diseases characterized by accelerated telomere shortening - such as dyskeratosis congenita - trigger a persistent DNA damage response (DDR) ³. This continuous DDR keeps PARP1 chronically activated. The combined consumptive pressure of hyperactive CD38 and chronically activated PARP1 severely restricts the bioavailability of NAD+ for sirtuins. Because sirtuins require NAD+ to regulate mitochondrial biogenesis, antioxidant defenses, and epigenetic stability, their suppression by NAD+ starvation exacerbates cellular senescence, establishing a destructive feed-forward loop that accelerates the aging phenotype ³¹⁰⁶.

Precursor Pharmacokinetics and Gut Microbiome Metabolism

To combat age-related NAD+ depletion, oral supplementation with NR and NMN has become a heavily researched intervention. Both molecules are orally bioavailable and effectively raise systemic NAD+ biomarkers, but their pharmacokinetic journey from the digestive tract to target tissues reveals an unexpected complexity driven heavily by the gut microbiome and the liver ¹³²⁴.

First-Pass Metabolism and Bacterial Deamidation

Initial hypotheses assumed that ingested NMN and NR were absorbed directly into the bloodstream and taken up intact by peripheral tissues. However, recent isotopic tracing studies confirm that oral NAD+ precursors are subjected to profound enzymatic alteration within the gastrointestinal tract long before reaching systemic circulation ²⁵¹⁵.

Rather than mammals independently processing these molecules, gut bacteria govern a substantial portion of NAD+ precursor metabolism. While mammalian hosts lack highly active deamidase enzymes, the gut microbiome encodes robust bacterial enzymes such as PncC and PncA ¹²²⁵²⁷. * PncC actively deamidates NMN into nicotinic acid mononucleotide (NaMN). * PncA converts nicotinamide (NAM) directly into nicotinic acid (NA).

When NMN or NR are administered orally, they are rapidly broken down into NAM in the intestinal lumen. The microbial PncA enzyme then deamidates this NAM into NA, effectively forcing the precursors into the deamidated Preiss-Handler pathway ¹²¹³¹⁴. This microbially derived NA enters the portal vein and is absorbed by the liver, driving the synthesis of hepatic NAD+ ¹³¹⁴.

The critical role of the microbiome in this process was definitively proven using germ-free or antibiotic-treated mice. Ablation of the gut microbiome prevented microbial deamidation, causing oral NMN to bypass the formation of deamidated intermediates (like NaMN and NaAD) and forcing it to metabolize purely through the canonical amidated salvage pathway ¹²²⁵²⁷. Human trials corroborate this microbial involvement. A 2026 direct comparative trial by Nestlé Health Science tracked 65 adults taking 1,000 mg of NR, 1,000 mg of NMN, or 500 mg of NAM daily for 14 days. The study demonstrated that while NR and NMN sustainably doubled circulating NAD+ levels, they did so primarily by modulating gut bacteria, which converted the precursors into NA ¹³. Additionally, both NR and NMN significantly increased the microbial production of short-chain fatty acids (SCFAs), which are known to fortify the intestinal barrier and exert systemic anti-inflammatory effects ¹³¹⁵.

Circulation and Tissue Uptake Limitations

Any fraction of ingested NMN or NR that escapes microbial digestion in the gut is swiftly subjected to severe first-pass metabolism in the liver. Pharmacokinetic studies tracking oral dosages across varied ranges (50 mg/kg to 500 mg/kg) consistently demonstrate that the liver nearly comprehensively converts any surviving intact NMN or NR into NAM ¹²¹⁶.

Consequently, only negligible trace amounts of intact oral NMN or NR reach the peripheral blood circulation ¹⁶¹⁷. Instead, peripheral organs predominantly rely on the secondary release of NAM and NA from the liver to synthesize their localized NAD+ pools. Because oral precursors operate primarily by enriching the systemic supply of fundamental building blocks rather than arriving intact at target tissues, achieving precise, tissue-specific physiological improvements remains a complex pharmacological challenge ¹⁶¹⁷³⁰.

Intravenous Administration Dynamics

Because of the heavy degradation inflicted by gastrointestinal microbiota and hepatic first-pass metabolism, intravenous (IV) administration of NAD+ and its precursors has gained traction in clinical environments. Intravenous delivery theoretically ensures 100% bioavailability in the bloodstream, bypassing digestive loss entirely ¹²³¹.

Biological Challenges of Intravenous Coenzymes

Despite widespread commercial marketing, infusing intact NAD+ (NAD+ IV) faces significant physiological limitations. The NAD+ molecule is exceptionally large, highly polar, and heavily phosphorylated, lacking specific transport channels to easily cross the cellular plasma membrane ²¹⁸³³. Pharmacokinetic monitoring reveals that when NAD+ is infused into the blood at rates of 3 μmol/min, it is rapidly catabolized in the extracellular space ¹⁹³³. Ectoenzymes present on the surface of endothelial and immune cells, such as CD38, CD73, and specific pyrophosphatases, aggressively cleave the circulating NAD+ into smaller, permeable components like NMN and NAM before tissues can utilize it ¹⁹³³.

Furthermore, NAD+ IV requires highly regulated, slow infusion rates - often spanning 4 to 6 hours for a standard 750 mg dose ³³¹⁹. Rapid spikes in extracellular NAD+ trigger immediate immune-like reactions via cell-surface purinergic receptors, resulting in severe flushing, gastrointestinal distress, and tachycardia ¹⁹³³.

Comparative Intravenous Precursor Therapy

Recent clinical research suggests that delivering precursors intravenously may offer a safer and pharmacokinetically superior alternative to infusing the fully formed coenzyme. A 2024 trial directly comparing NAD+ IV against NR IV evaluated systemic safety and biomarker responses. The study found that 500 mg of NR could be infused with minimal adverse effects in 75% less time than an equimolar dose of NAD+ ¹⁹³⁵.

Moreover, the precursor infusion demonstrated superior target engagement. While NAD+ IV failed to significantly elevate whole blood NAD+ within the first 24 hours, the NR IV group achieved a statistically significant 20.7% peak increase in whole-blood NAD+ concentrations at the 3-hour mark, outperforming both the NAD+ IV and an equivalent oral NR dose ¹⁹³⁵. These findings indicate that relying on smaller, easily transported precursor molecules bypasses both the gut microbiome and the extracellular degradation mechanisms, achieving acute systemic repletion with a superior safety profile ³³³⁵.

The Translational Gap in Clinical Efficacy

The rationale for NAD+ restoration therapies is rooted in profoundly successful preclinical animal models. However, translating these robust biological phenomena into human clinical outcomes has revealed a significant discrepancy, indicating that biochemical target engagement - successfully raising blood NAD+ - does not automatically confer physiological improvement ²⁰²¹.

Preclinical Lifespan and Metabolic Evidence

In rodents, augmenting NAD+ consistently reverses severe metabolic dysfunction, restores vascular elasticity, improves mitochondrial density, and bolsters physical endurance ¹⁰¹⁰²². Perhaps the most striking preclinical evidence emerged from a 2023 - 2024 study conducted by Harvard University researchers utilizing naturally aging C57BL/6 mice. The administration of 550 mg/kg/day of NMN in drinking water to mice starting at 13 months of age yielded a marked delay in frailty and a substantial modulation of the gut microbiome, notably increasing the presence of the anti-inflammatory bacteria Anaerotruncus colihominis ⁵³⁹. Crucially, the NMN treatment extended the median lifespan of female mice by 8.5% and the maximal lifespan by 7.9% ⁵³⁹. However, the treatment failed to significantly alter the lifespan of male mice, pointing to poorly understood sex-dependent metabolic variables in NAD+ utilization ⁵³⁹.

Skeletal Muscle and Physical Endurance in Humans

While aging humans universally experience sarcopenia - the progressive loss of skeletal muscle mass and function - clinical trials evaluating NAD+ precursors for muscle preservation have returned largely negative results. A comprehensive 2025 systematic review and meta-analysis pooled data from randomized controlled trials involving older adults (mean ages 60.9 to 83 years) administered NMN or NR ²³²⁴.

The meta-analysis concluded that supplementation provided no statistically significant improvements across major functional benchmarks ²³²⁴. Specifically, NMN failed to alter the skeletal muscle index (mean difference [MD]: - 0.42), grip strength (MD: 0.61), gait speed (MD: - 0.01), or the five-time chair stand test (MD: - 0.21) ²⁴. In patients with chronic kidney disease, a 6-week trial of 1,000 mg/day of NR showed no improvement in peak oxygen uptake or total work efficiency ²⁴. While isolated trials have reported minor enhancements in 6-minute walk distances or left-leg press strength under specific conditions, these signals routinely disappear when subjected to pooled analytical scrutiny, confirming that NAD+ boosters are not standalone interventions for age-related muscular decline ²³²⁴⁴².

Glycemic Control and Insulin Sensitivity

The most promising clinical signal for NAD+ precursors relates to metabolic health, though the benefits appear highly population-specific. In 2021, a landmark randomized controlled trial administered 250 mg of NMN daily for 10 weeks to overweight, postmenopausal women diagnosed with prediabetes ⁴²⁴³⁴⁴. The study utilized rigorous clamp testing and found that NMN improved skeletal muscle insulin sensitivity by approximately 25%, alongside upregulating genes associated with muscle remodeling ⁴²⁴⁴. Curiously, while muscle insulin signaling definitively improved, the total concentration of NAD+ within the biopsied muscle tissue did not rise, indicating that the metabolic benefit likely stems from rapid localized NAD+ turnover rather than sustained intracellular pooling ¹⁴⁴².

Despite this targeted success, meta-analyses of broader human populations demonstrate that NAD+ precursors do not universally improve glycemic metrics. Pooled data for fasting blood glucose show no significant effect for either NMN (MD: 0.02 mg/dL) or NR (MD: - 2.58 mg/dL) compared to placebo ²⁵⁴⁶. Similarly, HbA1c levels remain unchanged by both NMN (MD: - 0.01%) and NR (MD: - 0.20%) ²⁵. These data strongly suggest that while NAD+ restoration can repair specific metabolic deficits in impaired populations (e.g., prediabetes), it does not act as a metabolic enhancer in healthy, normoglycemic individuals ⁴³⁴⁴⁴⁶.

Dosage Asymmetries and Methodological Limitations

Direct comparisons of NMN and NR efficacy are heavily confounded by the lack of head-to-head clinical trials and severe methodological asymmetries in existing research. A detailed 2026 review identified massive disparities in the molar dosages administered across the literature. NMN trials - predominantly conducted in Asian populations - typically utilize conservative dosages of 250 to 300 mg per day, equating to roughly 0.78 mmol/day of the precursor ²⁵⁴⁶. Conversely, NR trials, frequently conducted in Western cohorts, regularly administer doses between 500 mg and 2,000 mg per day, yielding molecular intakes of up to 6.88 mmol/day ²⁵⁴⁶. This 5-to-9-fold molar discrepancy makes drawing definitive conclusions regarding the relative efficacy of NMN versus NR practically impossible until standardized, harmonized trials are completed ²⁵⁴⁶.

Summary of Human Clinical Trial Meta-Analytic Outcomes

Scientific Controversy and the Sirtuin Longevity Hypothesis

The commercial and scientific enthusiasm surrounding NAD+ restoration is heavily anchored in the "Information Theory of Aging," championed by prominent geroscientists such as David Sinclair at Harvard Medical School. This theory posits that biological aging is driven by a progressive loss of epigenetic fidelity and that sirtuins - relying on a steady supply of NAD+ - are uniquely capable of repairing DNA damage and resetting the epigenome to extend healthy lifespan ⁴⁷²⁶.

However, this specific mechanistic framework faces intense scrutiny and outright rejection from several prominent researchers in the metabolic field. Critics, led by Dr. Charles Brenner, argue that the foundational claims of the sirtuin longevity hypothesis rely on early methodological artifacts and heavily hyped counterfactuals ⁴⁷²⁷. In 2011, a major collaborative study conducted across seven distinct institutions systematically disproved the claim that sirtuin overexpression acts as a universal longevity switch, demonstrating that it did not inherently extend lifespan in yeast, worms, or fruit flies ²⁸.

Furthermore, the early assertion that plant polyphenols like resveratrol acted as direct sirtuin activators was later proven to be a laboratory artifact dependent on the specific fluorescent tags used in the assays ²⁶²⁸. This realization contributed to the pharmaceutical industry's most high-profile longevity failure when GlaxoSmithKline was forced to dissolve its $720 million acquisition of Sirtris Pharmaceuticals after the compounds failed to produce viable clinical results or demonstrate true sirtuin activation in humans ²⁸²⁹.

Recent debates have also centered on epigenetic reprogramming experiments utilizing Yamanaka factors (partial reprogramming). Critics emphasize that utilizing factors like the I-PpoI endonuclease to induce rapid aging and subsequent reversal introduces severe confounding variables, such as cell death via p53 pathways, and carries a significant risk of generating teratomas and malignant tumors if applied broadly in mammalian models ⁴⁷²⁶. Consequently, while NAD+ is universally recognized as a vital metabolic cofactor necessary for DNA repair and mitochondrial stability, the assertion that NAD+ precursors act through sirtuins as an anti-aging panacea remains highly contested ²⁷²⁸.

Safety Profiles and Oncology Risks

In the context of healthy, non-malignant human populations, the short-term safety profiles of oral NAD+ precursors are excellent. Meta-analyses of dozens of randomized trials evaluating NMN, NR, and NAM reveal no serious hepatotoxicity, renal damage, or physiological abnormalities at standard therapeutic doses (250 mg to 1,250 mg per day) over periods ranging from several weeks to six months ³⁰³⁰³¹. Reported side effects are generally limited to mild, transient gastrointestinal disturbances or minor fatigue ¹⁹³¹.

However, the manipulation of fundamental metabolic energy pathways carries significant theoretical risks regarding oncology. Because NAD+ is required for the survival, energy production, and DNA repair of all living cells, it is equally vital to cancer cells. Malignancy is a highly energy-intensive process, and aggressive tumors frequently upregulate the expression of the NAMPT enzyme to secure the massive quantities of NAD+ required to fuel unconstrained proliferation ¹³².

Preclinical studies indicate that artificially augmenting systemic NAD+ pools in the presence of an active malignancy can inadvertently shield tumors from targeted eradication ¹. A pivotal 2026 study conducted at Case Western Reserve University investigated the effects of NMN supplementation on pancreatic cancer models ³³. The researchers discovered that flooding the system with NMN severely undermined the efficacy of three standard chemotherapeutics: oxaliplatin, 5-fluorouracil, and gemcitabine ³³. The excess NAD+ allowed the pancreatic tumors to power up their energy systems, reduce treatment-induced oxidative stress, and efficiently repair the precise DNA damage that the chemotherapy was attempting to inflict, thereby preventing cancer cell death ³³.

Conversely, some preclinical models tracking early-stage liver cancer suggest that NR supplementation can improve DNA repair enough to prevent precancerous lesions from fully developing ³⁴. Nevertheless, the overarching consensus warns that while there is no evidence that NAD+ precursors act as direct carcinogens capable of causing cancer, their ability to act as high-octane cellular fuel poses a profound pro-tumorigenic risk for individuals with active malignancies or those undergoing cytotoxic chemotherapy ^1323334.

Global Regulatory Frameworks

The explosive consumer interest in anti-aging therapeutics has forced regulatory agencies worldwide to aggressively evaluate and categorize NAD+ precursors, leading to a highly fragmented legal landscape in 2025 and 2026.

United States Regulatory Reversal

In the United States, the regulatory status of NMN underwent a severe, multi-year controversy. NMN was initially sold widely as a dietary supplement. However, in November 2022, the U.S. Food and Drug Administration (FDA) abruptly revoked NMN's New Dietary Ingredient (NDI) status ³⁵³⁶. The FDA utilized the "drug preclusion clause" of the Dietary Supplement Health and Education Act (DSHEA), stating that because the pharmaceutical company MetroBiotech had previously submitted an Investigational New Drug (IND) application to study NMN as a clinical therapeutic, it was legally precluded from being marketed as a dietary supplement ³⁵³⁶.

The decision removed NMN from major e-commerce platforms and triggered a massive backlash from the nutraceutical industry ³⁶. The Natural Products Association (NPA) filed a joint citizen petition in early 2023, followed by a formal lawsuit against the FDA in August 2024, which secured a temporary court stay against FDA enforcement actions ³⁵⁵⁹.

This sustained pressure forced the FDA to reconsider its interpretation of the "race-to-market" provision. In a landmark policy reversal issued on September 29 - 30, 2025, the FDA released letters to major ingredient suppliers, concluding that verifiable evidence demonstrated NMN had been marketed as a food supplement in the U.S. prior to the authorization of the IND drug investigations ⁵⁹³⁷³⁸. Consequently, the FDA fully restored NMN's lawful status as a dietary supplement in the United States, ending a three-year period of market uncertainty ³⁵⁶².

European Union Novel Food Designations

In contrast, the European Union maintains a highly conservative stance. Under EU regulations, any food ingredient not significantly consumed within member states prior to May 1997 is classified as a "Novel Food" and requires extensive toxicological, pharmacokinetic, and stability validation by the European Food Safety Authority (EFSA) before it can be legally marketed ⁶³⁶⁴⁶⁵. Currently, NMN is classified as an unauthorized novel food, making its sale technically prohibited across the 28 EU member states ⁶³⁶⁵.

However, the regulatory pipeline advanced significantly in 2025. In February 2025, the NMN brand Uthever (produced by EffePharm) became the first to successfully complete the EU Novel Food public consultation phase, entering the final risk assessment stage ⁶⁴³⁹. Subsequently, on July 25, 2025, EFSA officially launched a safety assessment (dossier PC-1537) based on a comprehensive application submitted by the Chinese firm Shanghai Shangke Biotechnology ⁶⁷. Given EFSA's strict requirements - which historically grant an approval rating of roughly 30% - final authorization remains pending, though the industry anticipates a formal decision establishing a legal framework for NMN in the European market in the near future ⁶⁴⁶⁵.

Asian and Pacific Regulatory Stances

• Japan: Japan maintains the most permissive regulatory environment for NAD+ precursors. In 2020, the Ministry of Health, Labor, and Welfare (MHLW) officially approved NMN under its non-drug list, classifying it purely as a food ingredient. With no imposed dosage limits, Japan serves as a central global hub for NMN-based anti-aging innovation ⁶²⁶³.
• China: The regulatory environment in China remains paradoxical. While Chinese biotechnology firms manufacture the vast majority of the world's NMN supply, the National Health Commission stringently prohibits the use of NMN as a domestic food ingredient or dietary supplement. An application to classify NMN as a new food additive was explicitly rejected in May 2023 ⁶³. Thus, the Chinese industry operates strictly on an export model ⁶²⁶³.
• Australia: The Therapeutic Goods Administration (TGA) restricts the domestic sale of NMN. It is not currently recognized as an approved ingredient for therapeutic goods, meaning it cannot be legally marketed directly to Australian consumers without specific authorization, confining local manufacturers to export operations ⁶²⁶³.

Global NMN Regulatory Matrix (2025 - 2026)